- Joined
- Dec 2, 2010
- Messages
- 963
LOOK AT THESE STUDIES ....WOW
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).